These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9826580)

  • 1. OX-40: life beyond the effector T cell stage.
    Weinberg AD; Vella AT; Croft M
    Semin Immunol; 1998 Dec; 10(6):471-80. PubMed ID: 9826580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.
    Weinberg AD; Wegmann KW; Funatake C; Whitham RH
    J Immunol; 1999 Feb; 162(3):1818-26. PubMed ID: 9973447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
    Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
    Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
    Gramaglia I; Weinberg AD; Lemon M; Croft M
    J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis.
    Weinberg AD; Lemon M; Jones AJ; Vainiene M; Celnik B; Buenafe AC; Culbertson N; Bakke A; Vandenbark AA; Offner H
    J Neurosci Res; 1996 Jan; 43(1):42-9. PubMed ID: 8838572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease.
    Weinberg AD
    Mol Med Today; 1998 Feb; 4(2):76-83. PubMed ID: 9547794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
    Weinberg AD; Rivera MM; Prell R; Morris A; Ramstad T; Vetto JT; Urba WJ; Alvord G; Bunce C; Shields J
    J Immunol; 2000 Feb; 164(4):2160-9. PubMed ID: 10657670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
    Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
    J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of rat OX40 ligand by monoclonal antibody.
    Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
    Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo.
    Weatherill AR; Maxwell JR; Takahashi C; Weinberg AD; Vella AT
    Cell Immunol; 2001 Apr; 209(1):63-75. PubMed ID: 11414737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.
    Morris A; Vetto JT; Ramstad T; Funatake CJ; Choolun E; Entwisle C; Weinberg AD
    Breast Cancer Res Treat; 2001 May; 67(1):71-80. PubMed ID: 11518468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
    Yoshioka T; Nakajima A; Akiba H; Ishiwata T; Asano G; Yoshino S; Yagita H; Okumura K
    Eur J Immunol; 2000 Oct; 30(10):2815-23. PubMed ID: 11069062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.
    Huddleston CA; Weinberg AD; Parker DC
    Eur J Immunol; 2006 May; 36(5):1093-103. PubMed ID: 16541471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement.
    Weinberg AD; Evans DE; Thalhofer C; Shi T; Prell RA
    J Leukoc Biol; 2004 Jun; 75(6):962-72. PubMed ID: 14996827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
    Kuriyama H; Watanabe S; Kjaergaard J; Tamai H; Zheng R; Weinberg AD; Hu HM; Cohen PA; Plautz GE; Shu S
    Cell Immunol; 2006 Sep; 243(1):30-40. PubMed ID: 17207783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.
    Tsai HF; Lai JJ; Chou AH; Wang TF; Wu CS; Hsu PN
    Arthritis Rheum; 2004 Feb; 50(2):629-39. PubMed ID: 14872508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.
    Mestas J; Crampton SP; Hori T; Hughes CC
    Int Immunol; 2005 Jun; 17(6):737-47. PubMed ID: 15908450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of CD86 in BALB/c mice infected with Leishmania major does not prevent the expansion of low avidity T cells.
    Moro M; Filippi C; Gallard A; Malherbe L; Foucras G; Akiba H; Yagita H; Guéry JC; Glaichenhaus N
    Eur J Immunol; 2002 Dec; 32(12):3566-75. PubMed ID: 12516542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.
    Higgins LM; McDonald SA; Whittle N; Crockett N; Shields JG; MacDonald TT
    J Immunol; 1999 Jan; 162(1):486-93. PubMed ID: 9886424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.